Yes, salvigenin inhibits gastric cancer progression by targeting the EGFR/PI3K/AKT signaling pathway, which plays a critical role in tumor growth, survival, and aggressiveness. The study highlights the following key findings: 1.
Yes, salvigenin inhibits gastric cancer progression by targeting the EGFR/PI3K/AKT signaling pathway, which plays a critical role in tumor growth, survival, and aggressiveness. The study highlights the following key findings:
1. **Anticancer Properties of Salvigenin**: Salvigenin, a bioactive flavonoid, demonstrated significant anticancer effects in gastric cancer cells. It reduced cell proliferation, migration, and invasion while promoting apoptosis, effectively curbing the malignancy of gastric cancer.
2. **Mechanism of Action**: Mechanistic investigations using network pharmacology, molecular docking, and protein expression analyses revealed that salvigenin exerts its antitumor effects primarily by inhibiting the EGFR/PI3K/AKT signaling pathway. This pathway is well-known for its role in promoting tumor cell survival, proliferation, and metastasis.
3. **Validation of Mechanism**:
4. **Therapeutic Potential**: Salvigenin's ability to target a key oncogenic pathway (EGFR/PI3K/AKT) positions it as a promising candidate for targeted therapy in gastric cancer management. By reducing tumor aggressiveness and enhancing apoptosis, salvigenin offers a potential approach for improving outcomes in gastric cancer patients.
In summary, salvigenin's inhibition of the EGFR/PI3K/AKT signaling pathway is central to its anticancer effects, making it a potent agent for combating gastric cancer progression.
Introduction: Intrahepatic cholangiocarcinoma (ICC) is an aggressive primary liver cancer with poor prognosis and limited treatment options. While ICC has traditionally been considered a malignancy of biliary epithelial cells, increasing evidence suggests that hepatocytes can...
Introduction: Liver fibrosis is the key determinant of long-term outcomes in metabolic dysfunction-associated steatohepatitis (MASH). Activated hepatic stellate cells (HSCs) drive fibrogenesis, but effective antifibrotic therapies remain unavailable. This study investigated whether blocking the succinate–GPR91...
Introduction: The progression from metabolic dysfunction-associated fatty liver (MAFL) to metabolic dysfunction-associated steatohepatitis (MASH) is driven by complex interactions between hepatocytes and immune cells. This study identifies a novel spatial mechanism in the periportal (PP)...
Introduction: Cardiovascular–Kidney–Metabolic (CKM) syndrome recognizes the close interaction between obesity, type 2 diabetes, chronic kidney disease, and cardiovascular disease. This review highlights the emerging role of the gut microbiome, particularly butyrate-producing bacteria, as a central...
• Small intestinal adenocarcinoma (SIA) is a rare gastrointestinal cancer with limited disease-specific prognostic biomarkers and generally poor outcomes. • This nationwide Dutch population-based study evaluated whether three routinely available immunohistochemical markers—CK7, CK20, and CDX2—have...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) is closely linked to insulin resistance and type 2 diabetes, with the liver traditionally viewed as a key regulator of blood glucose through hepatic glucose production. However, emerging...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.